Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD40L-augmented TIL in Advanced Melanoma
NCT06961357Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2025
- Primary completion
- May 2029
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of CD40 ligand-augmented tumor-infiltrating lymphocytes in melanoma, sponsored by Moffitt Cancer Center. Started Dec 2025; status: recruiting.
02
Drugs
CD40 ligand-augmented tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06961357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961357.